Tema Oncology ETF (NASDAQ:CANC) Short Interest Update

Tema Oncology ETF (NASDAQ:CANC) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 7,200 shares, a growth of 453.8% from the February 13th total of 1,300 shares. Based on an average trading volume of 19,700 shares, the short-interest ratio is currently 0.4 days. Currently, 0.3% of the company’s shares are sold short.

Tema Oncology ETF Stock Performance

Tema Oncology ETF stock opened at $24.91 on Friday. The firm has a 50 day moving average price of $25.21 and a two-hundred day moving average price of $26.76. Tema Oncology ETF has a 52-week low of $23.97 and a 52-week high of $30.11. The firm has a market cap of $63.52 million, a price-to-earnings ratio of 26.86 and a beta of 1.11.

Institutional Investors Weigh In On Tema Oncology ETF

A hedge fund recently raised its stake in Tema Oncology ETF stock. Thrivent Financial for Lutherans boosted its position in Tema Oncology ETF (NASDAQ:CANC) by 29.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 517,837 shares of the company’s stock after acquiring an additional 118,328 shares during the period. Thrivent Financial for Lutherans owned 20.31% of Tema Oncology ETF worth $13,156,000 as of its most recent SEC filing.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.